Tuesday Mar 4
New Sources Of Revenue And Profitability Are In The Future For Dyax
Biotech companies are intriguing as possible investments not only for their potential stock gains, but also for their contributions to help improve and save the lives of individuals.
BRIEF-Pharming and Salix say FDA extended PDUFA date for angioedema drug Ruconest
If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links.